Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
Naseema Gangat, Rimal Ilyas, Kristen McCullough, Kebede H. Begna, Aref Al‐Kali, Mrinal M. Patnaik, Mark R. Litzow, William J. Hogan, Abhishek A. Mangaonkar, Hassan B. Alkhateeb, Mithun Vinod Shah, Michelle A. Elliott, James M. Foran, Talha Badar, Jeanne Palmer, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi
Abstract
Not available.
Topics & Concepts
VenetoclaxMyeloproliferative neoplasmHypomethylating agentMedicineOncologyInternal medicineNeoplasmMyelofibrosisLeukemiaPathologyBone marrowBiologyGeneticsChronic lymphocytic leukemiaGene expressionGeneDNA methylationMyeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia Treatments